You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲南白藥(000538.SZ):目前擁有247箇中成藥品種,共涉及354個批文,其中,獨家中成藥品種43個,獨家批文53個
格隆匯 05-19 16:26

格隆匯5月19日丨雲南白藥(000538.SZ)於2023年5月17日接受機構現場調研,問答環節中,就“國家鼓勵發展中醫藥,白藥在中藥領域有哪些佈局,以及有何戰略主張?”,公司回覆稱,黨和國家高度重視中醫藥發展,《“十四五”中醫藥發展規劃》提出建設高水平中醫藥傳承保護與科技創新體系、推動中藥產業高質量發展等促進中醫藥事業產業發展重點任務。

雲南白藥始終致力於推動傳統中醫藥融入現代生活,持續深挖傳統醫學產品的內生潛力,以產品創新迴應現代生活需求,不斷為傳統品牌及傳統中醫藥產品注入新的生命力。在醫藥產品領域,以傳承百年的雲南白藥散劑為起點,不斷開拓創新,逐漸形成了涵蓋氣霧劑、膏貼劑、酊劑、創可貼多種產品形態的雲南白藥核心藥品系列產品;在健康產品領域,將傳統雲南白藥產品與口腔護理產品相結合,成功地打造了以雲南白藥牙膏為主的口腔護理產品族羣,成為中醫藥企業跨界創新,重塑消費的經典案例。基於雲南白藥在藥品和健康產品領域的成功破局,公司目前已經建立了在天然藥物、中藥材飲片、特色藥、醫療器械、健康日化產品、保健食品等多個領域的業務佈局,實現了從一家傳統中藥製造企業向現代化大健康企業的轉型。

公司目前擁有247箇中成藥品種,共涉及354個批文,其中,獨家中成藥品種43個,獨家批文53個。公司一方面大力推動中藥品種的二次開發,另一方面以研發投入和科技力量推動中醫藥產品的創新。中藥產品二次開發方面,公司推進了宮血寧膠囊止血抗炎研究,並支持了研究者發起的千金藤素片抑制新冠病毒療效的研究。中藥新藥儲備方面,集中研發優勢資源孵化三款中藥1.1類新藥重點研發項目,包括治療心脈瘀阻證相關症狀的全三七片,用於温腎固本的我國首個獲批臨牀的證候類中藥新藥附杞固本膏,以及用於新冠肺炎恢復期、風寒型感冒相關證候者的香藿噴霧劑,並同步開展兩個經典名方(PZ-018、PZ-019)中藥製劑的開發。

未來,公司將繼續深耕中藥產業,持續推進中藥的現代化及科技化進程,充分利用本地得天獨厚的動植物資源,聚焦中藥、天然藥物的研究工作,保持公司在天然植物提取方面的傳統研發優勢,持續提升公司在中藥方面的自主研發能力及商業化能力,不斷推動傳統中醫藥在新時期的創新發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account